drugset
drugset / Trial / NCT04931667

3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis

NCT04931667 ↗

Phase 3 Terminated 72 enrolled Biosplice Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study is designed as a 3-year, multicenter, open-label study evaluating the safety, tolerability, and efficacy of intra-articular (IA) Lorecivivint (LOR) in subjects with osteoarthritis of the knee in a real-world setting.

Timeline

Start
2021-07-15
Primary completion
2021-12-13
Completion
2021-12-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Lorecivivint Small molecule 0.07 mg Other

Indications

osteoarthritis, knee